Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TKT | P29401 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | PPP5C | P53041 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PNPO | Q9NVS9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371360 | 0.88 | LMNA (0.61) | LMNATKTTDP1ESR1PTGS1 | |
| Pyrophosphoric Acid SCHEMBL851327 | 0.81 | LMNA (0.51) | LMNATKTTDP1 | |
| SCHEMBL5916304 | 0.80 | LMNA (0.50) | LMNATKTTDP1CYP3A4CYP2C19 | |
| SCHEMBL29727609 | 0.76 | LMNA (0.68) | LMNATKTTDP1 | |
| Phosphoric Acid SCHEMBL851329 | 0.74 | LMNA (0.53) | LMNATKTTDP1 | |
| SCHEMBL849877 | 0.74 | LMNA (0.53) | LMNATKTTDP1 | |
| Phosphoric Acid SCHEMBL1533803 | 0.74 | LMNA (0.53) | LMNATKTTDP1 | |
| Cocarboxylase SCHEMBL30192281 | 0.74 | LMNA (1.00) | LMNATKTTDP1PPP5C | |
| Cocarboxylase SCHEMBL80028 | 0.74 | LMNA (1.00) | LMNATKTTDP1PPP5C | |
| Hydrochloric Acid SCHEMBL7907624 | 0.73 | TKT (0.54) | LMNATKTTDP1PPP5CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119731312-A | Microbial cell factory for producing thiamine | 拜奥信尼亚私营有限责任公司 | 2025-03-28 | — | — | CN | claimed |
| CN-117897476-A | Microbial cell factory for producing vitamin B compounds | 拜奥信尼亚私营有限责任公司 | 2024-04-16 | — | — | CN | claimed |
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | PYRO PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | claimed |
| EP-1093520-A1 | HMP-P KINASE AND TMP-PPASE FROM ARABIDOPSIS THALIANA AND THEIR USE IN HERBICIDE SCREENING | Syngenta Participations AG (CH) | 2001-04-25 | — | — | EP | claimed |
| WO-2000000623-A1 | HMP-P KINASE AND TMP-PPASE FROM ARABIDOPSIS THALIANA AND THEIR USE IN HERBICIDE SCREENING | SYNGENTA PARTICIPATIONS AG (CH) | 2000-01-06 | — | — | WO | claimed |
| CN-119731312-A | Microbial cell factory for producing thiamine | 拜奥信尼亚私营有限责任公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-117897476-A | Microbial cell factory for producing vitamin B compounds | 拜奥信尼亚私营有限责任公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-2463654-B1 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | UNIV CALIFORNIA (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20150218597-A1 | USE OF THIAMINE AND NICOTINE ADENINE DINUCLEOTIDE FOR BUTANOL PRODUCTION | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-9012190-B2 | Use of thiamine and nicotine adenine dinucleotide for butanol production | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20120323047-A1 | USE OF THIAMINE AND NICOTINE ADENINE DINUCLEOTIDE FOR BUTANOL PRODUCTION | BUTAMAX(TM) ADVANCED BIOFUELS LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-8311790-B2 | Reverse engineering genome-scale metabolic network reconstructions for organisms with incomplete genome annotation and developing constraints using proton flux states and numerically-determined sub-systems | UNIVERSITY OF DELAWARE (US) | 2012-11-13 | — | — | US | disclosed |
| US-20060094075-A1 | Methods for indentifying compounds that modulate an enzyme in the coenzyme a biosynthetic pathway in a pathogenic microoganism | SCHECHTER ALAN M | 2006-05-04 | — | — | US | disclosed |
| US-20060063224-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway | SCHECHTER ALAN M | 2006-03-23 | — | — | US | disclosed |
| US-6955890-B2 | Method for the identification and treatment of pathogenic microorganisms infections by inhibiting one or more enzymes in an essential metabolic pathway | PYRO PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | PYRO PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030180830-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway | PYRO PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | disclosed |
| EP-1093520-A1 | HMP-P KINASE AND TMP-PPASE FROM ARABIDOPSIS THALIANA AND THEIR USE IN HERBICIDE SCREENING | Syngenta Participations AG (CH) | 2001-04-25 | — | — | EP | disclosed |
| EP-1059354-A2 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | Ceres Incorporated (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000000623-A1 | HMP-P KINASE AND TMP-PPASE FROM ARABIDOPSIS THALIANA AND THEIR USE IN HERBICIDE SCREENING | SYNGENTA PARTICIPATIONS AG (CH) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094075-A1 | Methods for indentifying compounds that modulate an enzyme in the coenzyme a biosynthetic pathway in a pathogenic microoganism | COASY, BPGM, ME1 | LMNA 3658/4885TKT 233/4885TDP1 3203/4885 |
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | CYP51A1, ME1, BPGM | LMNA 3872/4885TKT 24/4885TDP1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.